150 related articles for article (PubMed ID: 20042850)
1. Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature.
Gualco G; Ojopi EB; Chioato L; Cordeiro DL; Negretti F; Bacchi CE
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):291-5. PubMed ID: 20042850
[TBL] [Abstract][Full Text] [Related]
2. JAK2-positive cutaneous myelofibrosis presenting as sclerosing extramedullary hematopoietic tumors on the scalp: case presentation and review of the literature.
LeBlanc RE; Lester L; Kwong B; Rieger KE
J Cutan Pathol; 2015 Nov; 42(11):858-62. PubMed ID: 26153565
[TBL] [Abstract][Full Text] [Related]
3. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
4. Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression.
Morita K; Nakamine H; Inoue R; Takano M; Takeda M; Enomoto Y; Kasai T; Nonomura A; Tanaka H; Amano I; Morii T; Kimura H
Pathol Int; 2012 Jun; 62(6):433-7. PubMed ID: 22612514
[TBL] [Abstract][Full Text] [Related]
5. Sclerosing extramedullary hematopoietic tumor: emphasis on diagnosis by renal biopsy.
Sukov WR; Remstein ED; Nascimento AG; Sethi S; Lewin M
Ann Diagn Pathol; 2009 Apr; 13(2):127-31. PubMed ID: 19302963
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
Fraga GR; Caughron SK
Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
8. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders.
Remstein ED; Kurtin PJ; Nascimento AG
Am J Surg Pathol; 2000 Jan; 24(1):51-5. PubMed ID: 10632487
[TBL] [Abstract][Full Text] [Related]
9. Sclerosing Extramedullary Hematopoietic Tumor: A Case Report.
Wang D; Castro E; Rao A; McPhaul CM
J Investig Med High Impact Case Rep; 2020; 8():2324709620956463. PubMed ID: 32911987
[TBL] [Abstract][Full Text] [Related]
10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
11. Intraoral granulocytic sarcoma as a manifestation of myelofibrosis: A case report and review of the literature.
Nunes LFM; Rocha AL; Magalhães GHR; de Melo FHC; Travassos DV; Mesquita RA; Silva TA
Spec Care Dentist; 2018 Nov; 38(6):409-420. PubMed ID: 30188579
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
13. An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.
Maia RC; Bonamino MH; Robaina MC; Amaral N; Bonecker S; Zalcberg IR; Klumb CE
Blood Cells Mol Dis; 2015 Dec; 55(4):347-50. PubMed ID: 26460258
[TBL] [Abstract][Full Text] [Related]
14. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
15. Disseminated extramedullary myeloid tumor of the gallbladder without involvement of the bone marrow.
Bartley AN; Nelson CL; Nelson DH; Fuchs DA
Am J Hematol; 2007 Jan; 82(1):65-8. PubMed ID: 16947321
[TBL] [Abstract][Full Text] [Related]
16. Sclerosing extramedullary hematopoietic tumor presenting as an inguinal mass in a patient with primary myelofibrosis: a diagnostic pitfall.
Gu MJ
Int J Clin Exp Pathol; 2015; 8(3):3381-3. PubMed ID: 26045874
[TBL] [Abstract][Full Text] [Related]
17. Omental sclerosing extramedullary hematopoietic tumors in Janus kinase-2 negative myelofibrosis: caveat at frozen section.
Shinde SV; Shenoy AS; Balsarkar DJ; Shah VB
Indian J Pathol Microbiol; 2014; 57(3):480-2. PubMed ID: 25118752
[TBL] [Abstract][Full Text] [Related]
18. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation.
Stein BL; Moliterno AR
JAMA; 2010 Jun; 303(24):2513-8. PubMed ID: 20571018
[TBL] [Abstract][Full Text] [Related]
20. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
Gianelli U; Iurlo A; Cattaneo D; Lambertenghi-Deliliers G
Expert Rev Hematol; 2014 Apr; 7(2):255-64. PubMed ID: 24524231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
